Mechanism of Action and Effects on the Respiratory System
Both drugs act by blocking muscarinic cholinergic receptors. The primary pharmacological effect in the respiratory system is significant bronchodilation. The drugs block $M_3$ muscarinic receptors located on smooth muscle cells predominantly in large and medium bronchi, relieving bronchospasm and dilating the airways.
In addition to affecting muscle tone, these agents act on bronchial glands, effectively reducing their secretion. Clinically, this is a dual-edged process:
- On the one hand, the volume of secreted mucus decreases.
- On the other hand (and this is a significant clinical drawback), the total volume of sputum decreases while its viscosity increases markedly, making it considerably harder to clear and cough up.
Despite the thickening of mucus, these drugs possess an important positive property: they do not inhibit mucociliary clearance. The transport function of the ciliated bronchial epithelium remains preserved.
Differences Between Ipratropium and Tiotropium
Although both substances belong to the same pharmacological group, there is a critical difference in their receptor profile and selectivity.
Ipratropium bromide is a non-selective agent. It blocks all muscarinic receptor subtypes ($M_1$, $M_2$, $M_3$). Its binding to presynaptic $M_2$ receptors on nerve terminals leads to an undesirable effect: it disinhibits and increases the release of the neurotransmitter acetylcholine. This excess acetylcholine enters the synaptic cleft, where it begins to directly compete with ipratropium molecules, displacing the drug from receptors. As a result, the drug's efficacy can be limited.
Tiotropium bromide, conversely, exhibits kinetic selectivity. It reliably blocks airway $M_1$ and $M_3$ receptors while "sparing" (not blocking) presynaptic $M_2$ receptors. Consequently, excess acetylcholine is not released into the synaptic cleft. Furthermore, the drug dissociates very slowly from receptors, ensuring a prolonged and sustained effect (up to 24 hours versus 6–8 hours for ipratropium).
Pharmacokinetics and Safety Profile
Physicochemically, both ipratropium and tiotropium are quaternary ammonium compounds. This means they are strictly hydrophilic (polar) substances with low lipophilicity.
Upon inhalation, drug distribution occurs as follows:
- Only about 10% of the administered dose reaches the small bronchi and alveoli.
- The remaining major portion is deposited in the oropharynx and subsequently swallowed by the patient.
However, due to their pronounced polarity, these compounds cross biological membranes extremely poorly. They are practically not absorbed into the bloodstream either from the respiratory mucosa or from the gastrointestinal tract upon swallowing.
A consequence of such low systemic absorption is high safety: typical systemic (atropine-like) adverse effects are virtually absent. Only local reactions occur: dry mouth (resulting from salivary gland suppression) and increased sputum viscosity.
Clinical Application
The primary clinical field for inhaled antimuscarinics is pulmonology. They are used for obstructive airway diseases and bronchial asthma.
Special Role in COPD: These agents are drugs of choice. The pathogenesis of chronic obstructive pulmonary disease relies heavily on a pathological increase in vagus nerve cholinergic tone on bronchial tone. Antimuscarinics specifically and effectively counteract this influence.
- Ipratropium bromide begins acting within 15 minutes after inhalation.
- Tiotropium bromide (a long-acting agent) has a slower onset but is administered once daily specifically to prevent prolonged exacerbations.
Additional Indications:
- ENT Practice: Ipratropium is used as a nasal spray for vasomotor rhinitis to reduce rhinorrhea (suppressing nasal mucosal gland secretion).
- Cardiology: The drug "Itrop" (ipratropium bromide for intravenous and oral administration) is used for sinus bradycardia and heart blocks caused by excessive vagal tone, as it increases heart rate and atrioventricular conduction.